Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better

2026-06-03 15:09:14 ET

Eli Lilly (NYSE: LLY) has been posting incredible sales and earnings growth in recent quarters, thanks in no small part to its chronic weight management medicine, Zepbound. This therapy now generates higher sales than its main competitor, Wegovy, which has allowed Eli Lilly to take the top spot in the fast-growing anti-obesity market. However, Eli Lilly isn't just sitting on its laurels. The pharmaceutical leader is actively developing newer and better medicines in its core area of expertise. And recent clinical trial results for an investigational chronic weight management drug suggest it might have found its next gem. Let's look into what this means for investors.

Image source: The Motley Fool.

Zepbound's superior efficacy compared to Wegovy is partly because, while the latter mimics the action of the GLP-1 hormone (which helps regulate blood sugar and satiety), the former goes further. Zepbound is a dual GLP-1/GIP agonist. GIP also helps regulate blood sugar. Activating GLP-1 and GIP receptors simultaneously, as Zepbound does, appears to produce greater weight loss and metabolic benefits than activating GLP-1 alone. That brings us to retatrutide, Eli Lilly's next-gen weight-loss medicine that takes this concept even further by mimicking the action of three gut hormones: GLP-1, GIP, and glucagon.

Continue reading